Structure-Based Rational Design and Evaluation of BET-Aurora Kinase Dual-Inhibitors for Treatment of Cancers
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c01933 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Kaikai Lyu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China. Hauptthemen laut MEDLINE: Drug Design, Protein Kinase Inhibitors, Antineoplastic Agents, Aurora Kinase A. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology, Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Simultaneous inhibition of the bromodomain and extra-terminal domain and Aurora kinases is a promising anticancer therapeutic strategy. Based on our previous study on BET-kinase dual inhibitors, we employed the molecular docking approach to design novel dual BET-Aurora kinase A inhibitors. Through several rounds of optimization and with the guidance of the solved cocrystal structure of BRD4 bound to inhibitor 27, we finally obtained a series of highly potent dual BET-Aurora kinase A inhibitors. Compound 38 exhibited strong affinity toward both BRD4 and Aurora kinase A. It also showed good antiproliferative activities on diverse cancer cell lines, good pharmacokinetic profiles, and favorable antitumor efficacy in renal cell cancer and colon cancer xenograft models with TGI of 45.99% and 53.06%, respectively. The development of compound 38 reinforces the concept that a rational design may achieve dual inhibitors targeting specific kinases and bromodomain proteins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
- University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China.
- Jiangsu Key Laboratory of New Drug and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou 221006, China.
- State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
ORCID-Profile: Dong Guo, Bing Xiong
Förderung
- National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Lyu, K., Ren, Y., Mou, J., Yang, Y., Pan, Y., Zhang, H., Li, Y., Cao, D., Chen, L., Chen, D., Guo, D., & Xiong, B. (2025). Structure-Based Rational Design and Evaluation of BET-Aurora Kinase Dual-Inhibitors for Treatment of Cancers. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01933
Vancouver
Lyu K, Ren Y, Mou J, Yang Y, Pan Y, Zhang H, et al. Structure-Based Rational Design and Evaluation of BET-Aurora Kinase Dual-Inhibitors for Treatment of Cancers. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c01933
BibTeX
@article{Lyu2025,
author = {Lyu, Kaikai and Ren, Ying and Mou, Jie and Yang, Yunfang and Pan, Yaoyao and Zhang, Huijie and Li, Yanlian and Cao, Danyan and Chen, Lin and Chen, Danqi and Guo, Dong and Xiong, Bing},
title = {Structure-Based Rational Design and Evaluation of BET-Aurora Kinase Dual-Inhibitors for Treatment of Cancers},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c01933}
}
EUVIMED